Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various
cancers, including
melanomas. Indeed, various pro-tumorigenic functions of
PAI-1 in
cancer progression and
metastasis have been widely reported. Among them,
PAI-1 is also reported as a key regulator of PD-L1 expression on
melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1
antibodies (Abs). These findings suggested that
PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of
PAI-1 in
melanoma patients were evaluated, and the immunomodulatory effects of
PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of
PAI-1 showed that
PAI-1 expression on
melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of
PAI-1 were significantly decreased in responders compared to non-responders. Notably,
PAI-1 decreased the production of various
chemokines from monocyte-derived M2 macrophages in vitro, suggesting that
PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-
tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of
PAI-1 may be useful as a
biomarker for identifying patients with advanced cutaneous
melanoma most likely to benefit from anti-
melanoma immunotherapy.